EUR 0.22
(-4.48%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -17.5 Million EUR | 41.9% |
2022 | -34.06 Million EUR | 25.97% |
2021 | -46.01 Million EUR | -580.62% |
2020 | -6.76 Million EUR | 63.12% |
2019 | -18.33 Million EUR | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 Q1 | -4121.50 EUR | 35.08% |
2023 FY | -19.78 Million EUR | 41.9% |
2023 Q2 | -4121.50 EUR | 0.0% |
2022 FY | -34.06 Million EUR | 25.97% |
2022 Q4 | -6349.00 EUR | 0.0% |
2021 FY | -46.01 Million EUR | -580.62% |
2020 FY | -6.76 Million EUR | 63.12% |
2019 FY | -18.33 Million EUR | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
European Medical Solutions | -135 Thousand EUR | -12865.185% |
FERMENTALG | -11.8 Million EUR | -48.23% |
argenx SE | -417.15 Million EUR | 95.804% |
BioSenic S.A. | -7.04 Million EUR | -148.622% |
Celyad Oncology SA | -8.45 Million EUR | -106.965% |
Hyloris Pharmaceuticals SA | -15.99 Million EUR | -9.442% |
Onward Medical N.V. | -35.46 Million EUR | 50.644% |
Oxurion NV | -12.11 Million EUR | -44.533% |
PHAXIAM Therapeutics S.A. | -23.66 Million EUR | 26.023% |
Financière de Tubize SA | -2.14 Million EUR | -716.381% |
UCB SA | 604 Million EUR | 102.898% |